Changes in Serum Interleukin-8 and sRAGE Levels in Multiple Myeloma Patients

• Published in: Anticancer research 2020-03, Vol.40 (3), p.1443-1449
• Main Authors: Allegra, Alessandro, Pace, Elisabetta, Tartarisco, Gennaro, Innao, Vanessa, DI Salvo, Eleonora, Allegra, Andrea Gaetano, Ferraro, Maria, Musolino, Caterina, Gangemi, Sebastiano
• Format: Article
• Language: English
• Subjects: Advanced glycosylation end products; Aged; Animal models; Antigens, Neoplasm - blood; Bone diseases; Case-Control Studies; Cytokines; Disease Progression; Female; Females; Glycosylation; Humans; Interleukin 8; Interleukin-8 - blood; Male; Males; Mitogen-Activated Protein Kinases - blood; Multiple myeloma; Multiple Myeloma - blood; Multiple Myeloma - pathology
• ISSN: 0250-7005; 1791-7530
• DOI: 10.21873/anticanres.14086

Although numerous cytokines influence proliferation and progression of multiple myeloma (MM), a relevant action in the onset of the disease also seems to be played by the oxidative state. In the present study we evaluated the concentrations of interleukin-8 (IL-8) and soluble receptor of advanced glycation end products (sRAGE) in patients with MM, assessing the existing variations with respect to a control group and the possible existence of correlations between these molecules and the biological variables or the presence of a correlation between IL-8 and sRAGE. The study was conducted on 33 patients affected by MM compared to 39 healthy subjects. IL-8 and sRAGE levels were significantly higher in MM patients compared to healthy subjects. sRAGE and IL-8 evidence no significant linear correlation. Furthermore, IL-8 was significantly increased in both sexes, but we found a slight variation for females compared to males. IL-8 could play an important role in the onset of MM and the progression of bone disease, while the increased sRAGE values would seem to have a protective action in MM patients. Further studies on animal models may clarify the real impact of introducing modulation of IL-8 and sRAGE levels.